Related Experiment Video
Updated: Mar 7, 2026

Isolation Method for Long-Term and Short-Term Hematopoietic Stem Cells
Published on: May 19, 2023
Insurance systems and reimbursement concerning research and development of regenerative medicine in Japan
Kiyoshi Okada1,2, Toshio Miyata3, Yoshiki Sawa2,4
1Department of Orthopaedics, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, Japan.
Abstract:
In Japan, the Act on the Safety of Regenerative Medicine and the Pharmaceuticals, Medical Devices and Other Therapeutic Products Act were enacted in November 2014, creating a new framework for clinical research and products related to regenerative medicine. Together with these regulatory frameworks, new insurance procedures were created for handling regenerative medicine in Japan. For developing regenerative medicine in Japan, understanding medical insurance greatly influences funding and venture success, particularly in the stages between clinical research and market launch. The study aimed to identify the issues and examples surrounding Japan's present medical insurance system, especially for regenerative medicine. We believe that building stronger insurance systems for regenerative medicine is essential for internationally aligning and harmonizing the progress of regenerative medicine.
More Related Videos
Related Concept Videos
Health Information Technology and Healthcare Information System
Health Information Technology, commonly called HIT, integrates advanced information systems and technology in healthcare settings. Its primary functions include:
Secondary Healthcare System
EPS and iPS Cells in Disease Research
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Integrated Healthcare System
Drug Products: Biologics, Biosimilars and Interchangeables

